GL-0719 Phase 1 Clinical Trial Underway
GL-0719 is a recombinant Fc fusion protein in clinical trial designed to selectively inhibit the classical and lectin complement pathways, leaving intact the alternative and terminal complement pathways. GL-0719 is designed for treating autoimmune diseases caused by over-activation of the classical and lectin pathways.
GL-0719 is currently being dosed in a phase 1 study to assess safety, tolerability, drug levels, complement inhibition of each pathway, and complement component levels. GL-0719 is planned to be dosed intravenously and subcutaneously.
Learn More About GL-0719 »